| Zacks Company Profile for Arcus Biosciences, Inc. (RCUS : NYSE) |
|
|
| |
| • Company Description |
| Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Number of Employees: 627 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $8.59 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,106,802 shares |
| Shares Outstanding: 105.89 (millions) |
| Market Capitalization: $909.55 (millions) |
| Beta: 0.80 |
| 52 Week High: $18.98 |
| 52 Week Low: $6.50 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-10.52% |
-14.21% |
| 12 Week |
8.19% |
-5.20% |
| Year To Date |
-42.31% |
-45.51% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Terry Rosen - Chief Executive Officer
Robert C. Goeltz II - Chief Financial Officer
Kathryn Falberg - Director
Linda Higgins - Director
Yasunori Kaneko - Director
|
|
Peer Information
Arcus Biosciences, Inc. (CORR.)
Arcus Biosciences, Inc. (RSPI)
Arcus Biosciences, Inc. (CGXP)
Arcus Biosciences, Inc. (BGEN)
Arcus Biosciences, Inc. (GTBP)
Arcus Biosciences, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03969F109
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
|
|
Share - Related Items
Shares Outstanding: 105.89
Most Recent Split Date: (:1)
Beta: 0.80
Market Capitalization: $909.55 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-1.21 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-4.59 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 7.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 3.52% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/14/25 |
|
|
|
| |
